|
Racial/ethnic disparities in the effectiveness of atezolizumab plus bevacizumab (A+B) vs. tyrosine kinase inhibitors (TKIs) among veterans with unresectable hepatocellular carcinoma (uHCC). |
|
|
|
Consulting or Advisory Role - Roche/Genentech |
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); Exact Sciences (Inst); Gilead Sciences (Inst); Glycotest (Inst) |
Patents, Royalties, Other Intellectual Property - Glypican-3 Chimeric Antigen Receptor (Inst) |
|
|
|
Stock and Other Ownership Interests - Genentech/Roche |
Travel, Accommodations, Expenses - Roche/Genentech |
|
|
Consulting or Advisory Role - Genentech (Inst) |
|
|
Consulting or Advisory Role - Genentech |
|
|
|
Stock and Other Ownership Interests - Genentech |
Research Funding - Genentech |
Patents, Royalties, Other Intellectual Property - HPK1 target as immunotherapy; HPK1 target as immunotherapy |
Travel, Accommodations, Expenses - Genentech |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Boston Scientific; Eisai; Exact Sciences; Exelixis; FjuFilm Medical Sciences; Freenome; Genentech; Glycotest; GRAIL; Histosonics |
Research Funding - Glycotest |